Other languages Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Real-time Estimate Cboe BZX Other stock markets 12:49:18 02/05/2024 am IST			5-day change	1st Jan Change
3.315 ^USD	+2.95%		+5.35%	-12.76%

04/04	Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	MT
04/04	Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04/04
Borsa svizzera chiude in rialzo, SMI +0,64%	04/04
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04/04
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals	04/04
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04/04
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	28/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals, Inc. Presents Sabirnetug Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting	08/03
Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer	01/02
Acumen Pharmaceuticals Secures $50 Million Credit Facility	13/11
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Halozyme Therapeutics Signs Non-Exclusive License Deal With Acumen Pharmaceuticals for Enhanze Technology	06/11
Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease	27/23/27
Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer?s During Symposium At the 16Th Annual Clinical Trials on Alzheimer?s Disease	04/23/04
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
Acumen Pharmaceuticals Prices Upsized $130 Million Common Stock Offering	19/23/19
Wall Street sluit hoger	19/23/19
Wall Street op winst	19/23/19
Top Midday Decliners	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Other languages

Filters